Mirum Pharmaceuticals (MIRM) Free Cash Flow (2019 - 2026)

Mirum Pharmaceuticals' Free Cash Flow history runs 8 years deep, the most recent figure standing at -$229.4 million for Q1 2026.

• On a quarterly basis, Free Cash Flow fell 11359.89% year-over-year to -$229.4 million in Q1 2026; TTM through Mar 2026 was -$172.6 million, a 2092.81% decrease from a year earlier, with the FY2025 full-year figure at $54.9 million, up 488.01% from the prior year.
• Free Cash Flow fell to -$229.4 million in Q1 2026 per MIRM's latest filing, from $5.5 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $39.5 million in Q3 2025 and bottomed at -$229.4 million in Q1 2026.
• The 5-year median for Free Cash Flow is -$16.6 million (2023), against an average of -$21.0 million.
• Across the five-year window, Free Cash Flow surged 938.5% in 2025 and slumped 11359.89% in 2026, its largest moves.
• Year by year, Free Cash Flow stood at -$34.5 million in 2022, then surged by 51.85% to -$16.6 million in 2023, then jumped by 69.38% to -$5.1 million in 2024, then soared by 207.45% to $5.5 million in 2025, then slumped by 4296.58% to -$229.4 million in 2026.
• Per Business Quant, the three latest MIRM Free Cash Flow figures stand at -$229.4 million (Q1 2026), $5.5 million (Q4 2025), and $39.5 million (Q3 2025).